Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized first-line chemotherapy study in metastatic HER2-negative breast cancer
2005-000438-19Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Oral vinorelbine + capecitabine, Gemcitabine + paclitaxel and Gemcitabine + docetaxel (3 arms). Primary endpoint: Overall response rate. Started Oct 2005; status: completed.
02
Drugs
vinorelbinecapecitabinegemcitabinepaclitaxeldocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000438-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000438-19.